US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Report on Operations 2018: High profitability and good organic growth

    Fourth quarter · Sales amounted to SEK 320 (271) million, corresponding to an increase of 18 percent in SEK. Sales increased by 12 percent in local currency and consisted of organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 135 (103) million, corresponding to a margin of 42 (38) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 11 million. · Net income amounted to SEK 84 (69) million, which gave earnings per share of SEK 0.77 (0.63). · Licensing and commercialisation agreement with Illumina Inc., regarding

    Report on operations 2017: Continued profitable growth

    Fourth quarter: ·  Sales amounted to SEK 271 (251) million, corresponding to an increase of 8 percent in SEK. Sales growth was 11 percent in local currency and consisted in its entirety of organic growth. ·  Operating income before depreciation and amortisation (EBITDA) amounted to SEK 103 (96) million, corresponding to a margin of 38 (38) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 5 million. ·  Net income amounted to SEK 69 (60) million, which gave earnings per share of SEK 3.15 (2.74). Whole year 2017: ·  Sales amounted to SEK 1 046 (856)

    Conference call Report on Operations 2016

    Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2016. The presentation will be held in English.Time: Thursday February 9, 2017 at 10.00 a.m. CET. Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +46 (0)8 5052 0337  UK dial in number: +44 (0)20 7162 9960  Conference name: Vitrolife, conference ID: 961247 Vitrolife participants:Thomas Axelsson, CEO Mikael Engblom, CFOThe press release for Vitrolife’s Report on Operations will be released at 8.30 CET on the

    Report on operations 2014: Acquisition of FertiliTech and strengthened income

    Fourth quarter · Acquisition of all the shares in Unisense FertiliTech A/S (“FertiliTech”), the market leader in embryo monitoring, time-lapse, for IVF. · Non-cash issue of 1,879,179 shares for part-financing of the acquisition of FertiliTech. · Sales amounted to SEK 137 (124) million, corresponding to an increase of 11 percent in SEK. Sales growth was 4 percent in local currency. Last year’s figure included sales of the transplant product STEEN Solution™ to Xvivo to the tune of SEK 5 million. Adjusted for this, the increase in sales amounted to 8 percent in local currency. ·

    Report on operations 2013: High growth and improved profitability

    Fourth quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 124 (98) million, corresponding to an increase of 26 percent in SEK. · Operating income (EBIT) amounted to SEK 22 (12) million, corresponding to an operating margin of 18 (12) percent. The quarter was affected by the write-down of intangible assets with regard to Labware to the tune of SEK 9 (-) million. · The comparative figures for 2012 relate to continuing operations, Fertility, unless otherwise stated. · Net income amounted to SEK 15 (0) million, which gave

    Report on operations 2012

    High growth and improved operating marginFourth quarter Continuing operations: · Sales growth was 24 percent in local currency. Sales amounted to SEK 98 (82) million, corresponding to an increase of 20 percent in SEK. · Operating income (EBIT) amounted to SEK 12 (2) million, corresponding to an operating margin of 12 (2) percent. · On October 1 the transplantation business was distributed to the shareholders of Vitrolife, and it is thus reported in this interim report as discontinued operations. The distribution entailed a non-taxable financial capital gain of SEK 303 million

    Report on operations 2011

    A quarter of record sales and one-time expensesFourth quarter · Sales increased by 19 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 95 (81) million, corresponding to an increase of 18 percent in SEK. · Operating income (EBIT) amounted to SEK 4 (9) million. The operating margin was 4 (11) percent. One-time expenses of SEK 7 million are included and consist of remuneration to the former CEO, write-down for a development project and disposal of production equipment. EBIT excluding one-time expenses amounted to SEK 11 million,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe